EVEREST MED: Performance is expected to grow significantly by 142% in 2025, achieving a turnaround to profitability
36Kr learned that the Hong Kong innovative pharmaceutical company EVEREST MED disclosed its full-year performance report for 2025. The data shows that the company achieved total revenue of 1.707 billion yuan in 2025, a significant increase of 142%; it turned a profit under Non-IFRS standards, earning 187 million yuan, and achieved positive operating cash flow in the fourth quarter. As of December 31, 2025, the company had ample cash reserves of 2.731 billion yuan, strongly supporting commercialization expansion, independent research and development, and medium to long-term strategic layout
Source: 36Kr The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments